Exploring New Applications for Antigen-Specific In Vivo Treg Induction Platforms

2:30 pm - Thursday 25th March 2027

  • Evaluating preclinical evidence supporting the use of antigen-specific Treg induction beyond the platform’s initial disease focus
  • Optimizing platform design to reduce dosing burden and improve patient accessibility while maintaining therapeutic activity
  • Leveraging insights from preclinical development to accelerate the translation of nextgeneration immune tolerance therapies

Speakers:

Chief Executive Officer
Parvus Therapeutics